Affimed(US:AFMD) Newsfilter·2024-05-28 10:30Core Viewpoint - Affimed N.V. is set to hold its 2024 Annual General Meeting of Shareholders on June 26, 2024, in Amsterdam, focusing on its commitment to advancing immuno-oncology therapies for cancer treatment [1]. Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company dedicated to enhancing patients' innate ability to combat cancer through its innovative innate cell engagers (ICE®) [2]. - The company's proprietary ROCK® platform is utilized to create customized molecules that harness the innate immune system to target and eliminate various hematologic and solid tumors [2]. - Affimed is headquartered in Mannheim, Germany, and is led by a team of experienced professionals in biotechnology and pharmaceuticals, aiming to prevent cancer from disrupting patients' lives [2].